Credit Suisse analyst Dan Leonard lowered the firm’s price target on Illumina to $200 from $225 and keeps a Neutral rating on the shares following Q2 results and sharply reduced guidance. The firm says its positive view of the company’s market position in next-generation sequencing is offset by concerns that forward Street estimates are too high.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ILMN:
- Illumina names Dr. Steven Barnard as Chief Technology Officer
- Illumina sees customers ‘more cautious in their purchasing’ in 2H23
- Illumina Reports Financial Results for Second Quarter of Fiscal Year 2023
- Illumina cuts FY23 adjusted EPS view to 75c-90c from $1.25-$1.50
- Illumina reports Q2 adjusted EPS 32c, consensus 2c